Metformina Almus

Metformin Hydrochloride, the active ingredient in Metformina Almus, is a biguanide presented as a tablet for oral use. It lowers elevated blood glucose by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, making it a cornerstone therapy for adults diagnosed with type 2 diabetes mellitus.

GNH USA supplies Metformina Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across European and global markets through robust quality‑assured manufacturing and reliable logistics.

Metformina Almus (metformin) is indicated for the management of hyperglycaemia within the type 2 diabetes mellitus therapeutic pathway.

- Type 2 diabetes mellitus: improves glycaemic control by reducing fasting and post‑prandial glucose levels.

Metformina Almus may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Metallic taste in the mouth. - Mild headache. - Decreased appetite. - Weight loss.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal accumulation of lactic acid. - Severe hypoglycaemia when combined with other glucose‑lowering agents. - Hepatic dysfunction. - Allergic reactions: rash, pruritus, or angio‑edema. - Vitamin B12 deficiency with long‑term use.

Before initiating therapy, clinicians should assess renal function, hepatic status, and potential contraindications.

- Renal function assessment: avoid use in patients with eGFR <30 mL/min/1.73 m². - Hepatic disease monitoring: use cautiously in active liver disease. - Cardiovascular status: monitor for signs of heart failure exacerbation. - Concomitant alcohol intake: advise limitation to reduce lactic acidosis risk. - Pregnancy and lactation: evaluate risk‑benefit ratio with a healthcare professional. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Metformina Almus can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure; discontinue metformin before and after imaging. - Cimetidine: can increase metformin plasma concentrations. - Nucleoside reverse transcriptase inhibitors (e.g., didanosine): heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics (loop or thiazide): can affect renal clearance of metformin. - Corticosteroids: may raise blood glucose, requiring dose adjustment. - ACE inhibitors/ARBs: monitor renal function when used together.